Haematologica. 2020 Dec 1; 105(12): 2738–2745.
Published online 2020 Oct 9. doi: 10.3324/haematol.2019.242891
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Ehab Atallah1 and Charles A Schiffer2
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
While the world eagerly awaits an effective vaccine, the current focus is on drug treatments. One such agent, the corticosteroid dexamethasone, has garnered considerable interest due to favourable findings from a recent study out of the UK. Remdesivir and several other agents have also been described as possibly effective treatments. Unfortunately....
In order to harmonize and standardize the management of patients with chronic myeloid leukemia (CML), the European LeukemiaNet (ELN) produced recommendations in the previous years. ELN gathered CML experts to define concepts and formulate the first recommendations for treating CML in 2006 [1]. The remarkable progress in the field of CML mandated updating of these recommendations in 2009 [2], 2013 [3], and recently in 2020 [4].
https://www.tandfonline.com/doi/full/10.1080/17474086.2020.1813564
Authors: Graeme Smith Jane Apperley Dragana Milojkovic Nicholas C. P. Cross Letizia Foroni Jenny Byrne Andy Goringe Anupama Rao Jamshid Khorashad Hugues de Lavallade Adam J. Mead Wendy Osborne Chris Plummer Gail Jones Mhairi Copland behalf of British Society for Haematology
Press Release
Key Points
A really interesting paper on the management and incidence of COVID-19 in CML patients in Italy
https://www.nature.com/articles/s41375-020-0904-z.pdf
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024).
As the UK and the world see many more people test positive for COVID-19 You can help collect important data with this free symptom tracker by monitoring your day to day health and wellbeing.